HitGen Partner BioAge Labs Doses First Participant in Phase 2 Trial of BGE-102, a Novel Oral NLRP3 Inhibitor for Cardiovascular Risk Reduction

CHENGDU, China, July 14, 2026 /PRNewswire/ -- Shanghai Stock Exchange listed company HitGen Inc. ("HitGen", SSE: 688222.SH), congratulates its partner BioAge Labs, Inc. ("BioAge", NASDAQ: BIOA), a clinical-stage biopharmaceutical company developing therapeutic product candidates for...

Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.